| http://www.w3.org/ns/prov#value | - Additionally, several other companies such as Pfizer and Convergence Pharmaceuticals are developing oral agents that selectively block promising ion channel targets, which we continue to follow with interest.??? The report also finds that opioid analgesics and NSAIDs will remain entrenched in the treatment algorithm for pain and comprise at least 45 percent of total sales in the pain market over t
|
